Aseptic meningitis with elevated adenosine deaminase (ADA) after interruption of antiretroviral treatment [4];Meningitis aséptica con ADA elevado tras interrupción del tratamiento antirretroviral

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 24, Issue 2, 2006, Pages 138-139

  Sorli, Luisa ^a   Tellez, Eloisa ^a   Taverner, Delia ^a   Knobel, Hernando ^a  

^a HOSPITAL DEL MAR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; ANTIRETROVIRUS AGENT;

ADULT; ANTIVIRAL ACTIVITY; ASEPTIC MENINGITIS; CASE REPORT; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LETTER; MALE; VIRUS DETECTION;

EID: 33645416568     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13085025     Document Type: Article

References (7)

1. Iribarren JA, Labarga P, Rubio B, Berenguer J, Miró JM, Antela A, et al. Recomendaciones GESIDA/Plan nacional sobre el SIDA respecte al tratamiento antiretroviral en pacientes adultes infectados por el VIH (Octubre 2004). Enferm Infecc Microbiol Clin. 2004;22:564-642.
2. Worthington MG, Ross JJ. Aseptic meningitis and acute HIV syndrome after interruption of antiretroviral therapy: implications for structured treatment interruptions. AIDS. 2003;17:2145-6.
3. Corral I, Quereda C, Navas E, Martín-Dávila P, Pérez-Elías MJ, Casado JL, et al. Adenosine deaminase activity in cerebroespinal fluid of HIV-infected patientes: limited value for diagnosis of tuberculosis meningitis. Eur J Clin Microbiol Infect Dis. 2004;23:471-6.
4. López-Cortés LF, Cruz-Ruiz M, Gómez-Mateos J, Jiménez-Hernández D, Jiménez-Mejías E, Pachon J, et al. Adenosine deaminase activity in the CSF of patients with aseptic meningitis: utility in the diagnosis of tuberculous meningitis or neurobrucellosis. Clin Infect Dis. 1995;20:525-30.
5. Cervero-Jiménez M, Torres-Perea R, Ruiz-Capillas J, Del Alamo M, Agut JL, Solís J, et al. Factures que predicen el fracaso de las interrupciones del tratamiento antirretroviral (TAR) en los pacientes con infección por el VIH. Enferm Infecc Microbiol Clin. 2005;23:202-7.
6. Skiest DJ, Morrow P, Allen B, McKinsey J, Crosby C, Foster B, et al. It is safe to stop antiretroviral therapy in patients with preantiretroviral CD4 cell counds > 250 cell/fiL. J Adquir Immune Defic Syndr. 2004;37:1351-7.
7. Wit FW, Blanckenberg DH, Brinkman K, Prins JM, Van der Ende ME, Schneider MM, et al. Safety of long-term interruption of successful antiretroviral therapy: the ATHENA cohort study. AIDS. 2005;19:341-50.